Evidence map›Paper›PMID 42694817›Full record

ReviewRSC medicinal chemistry2026

Three privileged scaffolds, one pipeline: chalcones, pyrazolines and pyrazoles in drug discovery and fluorescent sensing.

Alexander Ciupa

Abstract readReview
In one paragraph

Review in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alexander CiupaMaterials Innovation Factory, University of Liverpool 51 Oxford Street Liverpool L73NY UK ciupa@liverpool.ac.uk.ORCID https://orcid.org/0009-0006-3646-3797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chalcones, pyrazolines, and pyrazoles constitute a uniquely powerful discovery pipeline in which each is a privileged scaffold with distinct applications, while also serving as the synthetic precursor to the next. Despite a theoretical chalcone library exceeding 680 000 unique structures accessible from commercial starting materials alone, fewer than 5140 examples have been reported in the literature-representing just 0.8% of this chemical space. Combining this precursor library with the downstream pyrazoline and pyrazole chemical spaces yields a combined landscape conservatively estimated to exceed 7.5 million unique structures, which remains largely unexplored. This review examines leading examples from 1990 to 2025 across all three scaffold classes, with particular emphasis on the most promising applications of this pipeline: anti-cancer, anti-inflammatory, anti-viral, and fluorescent sensing applications. We explore how pharmacophore hybridisation is further expanding this pipeline. Whereas previous reviews have focused on individual scaffold classes in isolation, this review takes an integrated, systematic approach that unifies all three into a single coherent discovery pipeline. We conclude with a roadmap on how the convergence of design of experiments, automated synthesis, high-throughput screening, and machine learning will unlock the potential of this vastly unexplored chemical space.

Identifiers

PMID42694817
PMCPMC13539734

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.